FSD Pharma Past Earnings Performance
Past criteria checks 0/6
FSD Pharma has been growing earnings at an average annual rate of 2%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 84.9% per year.
Key information
2.0%
Earnings growth rate
40.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 84.9% |
| Return on equity | -141.2% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How FSD Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -18 | 13 | 4 |
| 30 Sep 23 | 0 | -23 | 14 | 7 |
| 30 Jun 23 | 0 | -29 | 16 | 8 |
| 31 Mar 23 | 0 | -31 | 19 | 8 |
| 31 Dec 22 | 0 | -27 | 16 | 7 |
| 30 Sep 22 | 0 | -27 | 17 | 5 |
| 30 Jun 22 | 0 | -25 | 16 | 3 |
| 31 Mar 22 | 0 | -30 | 19 | 5 |
| 31 Dec 21 | 0 | -34 | 23 | 6 |
| 30 Sep 21 | 0 | -32 | 22 | 8 |
| 30 Jun 21 | 0 | -39 | 25 | 12 |
| 31 Mar 21 | 0 | -30 | 20 | 9 |
| 31 Dec 20 | 0 | -28 | 18 | 8 |
| 30 Sep 20 | 0 | -36 | 21 | 5 |
| 30 Jun 20 | 0 | -35 | 20 | 2 |
| 31 Mar 20 | 0 | -41 | 24 | 0 |
| 31 Dec 19 | 0 | -34 | 20 | 0 |
| 30 Sep 19 | 0 | -38 | 27 | 0 |
| 30 Jun 19 | 0 | -25 | 22 | 0 |
| 31 Mar 19 | 0 | -16 | 18 | 0 |
| 31 Dec 18 | 0 | -17 | 17 | 0 |
| 30 Sep 18 | 0 | -2 | 7 | 0 |
| 30 Jun 18 | 0 | -7 | 7 | 0 |
| 31 Mar 18 | 0 | -4 | 4 | 0 |
| 31 Dec 17 | 0 | -3 | 3 | 0 |
Quality Earnings: 0K9 is currently unprofitable.
Growing Profit Margin: 0K9 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0K9 is unprofitable, but has reduced losses over the past 5 years at a rate of 2% per year.
Accelerating Growth: Unable to compare 0K9's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0K9 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Return on Equity
High ROE: 0K9 has a negative Return on Equity (-141.22%), as it is currently unprofitable.